Abstract
Background
Ischemic (ISCM) and idiopathic dilated (IDCM) cardiomyopathies have different responses to therapy and outcomes. Both may demonstrate elevations in troponin and B‐type natriuretic peptides, but biomarker levels have not been reported to differ as a function of the etiology of heart failure (HF). Accordingly, we compared these biomarkers in patients with chronic HF.
Hypothesis
Biomarker levels of troponin T, troponin I, B‐type natriuretic peptide (BNP), and N‐terminal prohormone brain natriuretic peptide (NT‐proBNP) are quantitatively different between ischemic and idiopathic dilated etiologies of chronic HF.
Methods
Forty patients (27 male, 68 ± 2 years; LVEF 25 ± 1%; NYHA Class III–IV) admitted to hospital for acute HF were studied. Biomarkers were drawn at admission prior to treatment intervention.
Results
Of the 40 patients, 27 had ISCM and 13 IDCM. Baseline clinical characteristics were similar with the exception of GFR. cTnT, cTnI, and BNP levels were higher in ISCM patients (cTnT: 0.373 ± 0.145 vs. 0.064 ± 0.016 ng/mL, p < 0.05; cTnI: 2.02 ± 0.76 vs. 0.21 ± 0.11 ng/mL, p < 0.05; BNP: 776 ± 91 vs. 532 ± 85 pg/mL, p < 0.05). Cardiovascular mortality during follow up (10 ± 1 months) was 48% in patients with ISCM and 23% with IDCM (p < 0.05).
Conclusions
Patients with acutely decompensated chronic HF have elevations in troponin and BNP. These elevations, as well as mortality are significantly higher in patients with ISCM compared to IDCM. The differential levels in biomarkers may be due to differences in disease pathogenesis, and fit with the adverse prognosis in these patients. Copyright © 2007 Wiley Periodicals, Inc.
Keywords: cardiomyopathy, troponin, NT‐proBNP, BNP, heart failure, outcomes
Full Text
The Full Text of this article is available as a PDF (259.4 KB).
References
- 1. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, et al.: The OPTIME‐CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure. J Am Coll Cardiol 2003; 41: 997–1003. [DOI] [PubMed] [Google Scholar]
- 2. Tsagalou EF, Anastasiou‐Nana MI, Terrovitis JV, Nanas SN, Alexopoulos GP, et al.: The long‐term survival benefit conferred by intermittent dobutamine infusions and oral amiodarone is greater in patients with idiopathic dilated cardiomyopathy than with ischemic heart disease. Int J Cardiol 2006; 108: 244–250. [DOI] [PubMed] [Google Scholar]
- 3. Stevenson LW, Tillisch JH, Hamilton M, Luu M, Chelimsky‐Fallick C, et al.: Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990; 66: 1348–1354. [DOI] [PubMed] [Google Scholar]
- 4. Bart BA, Shaw LK, McCants CB Jr, Fortin DF, Lee, KL , et al.: Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30: 1002–1008. [DOI] [PubMed] [Google Scholar]
- 5. Likoff MJ, Chandler SL, Kay HR: Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987; 59: 634–638. [DOI] [PubMed] [Google Scholar]
- 6. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, et al.: Underlying cause and long‐term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077–1084. [DOI] [PubMed] [Google Scholar]
- 7. Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, et al.: Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002; 89: 691–695. [DOI] [PubMed] [Google Scholar]
- 8. Healey JS, Davies RF, Smith SJ, Davies RA, Ooi DS: Prognostic use of cardiac troponin T and troponin I in patients with heart failure. Can J Cardiol 2003; 19: 383–386. [PubMed] [Google Scholar]
- 9. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, et al.: Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369–374. [DOI] [PubMed] [Google Scholar]
- 10. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, et al.: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–147. [DOI] [PubMed] [Google Scholar]
- 11. Miller WL, Burnett JC, Hartman KA, Henle MP, Burritt MF, et al.: Lower rather than higher levels of B‐type natriuretic peptides (BNP and NT‐Pro BNP) predict short‐term mortality in end‐stage heart failure patients treated with nesiritide. Am J Cardiol 2005; 96: 837–841. [DOI] [PubMed] [Google Scholar]
- 12. Narula J, Haider N, Virmani R, DiSalva TG, Kolodgie FD, et al.: Apoptosis in myocytes in end‐stage heart failure. N Engl J Med 1996; 335: 1182–1189. [DOI] [PubMed] [Google Scholar]
- 13. Perna ER, Macin SM, Cimbaro Canella JP, Augier N, Riera Stival JL, et al.: Ongoing myocardial injury in stable severe heart failure. Value of cardiac troponin T monitoring for high‐risk patient identification. Circulation 2004; 110: 2376–2382. [DOI] [PubMed] [Google Scholar]
- 14. Hudson MP, O'Connor CM, Gattis WA, Tasissa G, Hasselblad V, et al.: Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 2004; 147: 546–552. [DOI] [PubMed] [Google Scholar]
- 15. Horwich TB, Patel J, MacLellan R, Fonarow GC: Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833–838. [DOI] [PubMed] [Google Scholar]
- 16. Sato Y, Kita T, Takatsu Y, Kimura T: Biochemical markers of myocyte injury in heart failure. Heart 2004; 90: 1110–1113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Konstam MA: Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 2005; 96: 867–871. [DOI] [PubMed] [Google Scholar]
- 18. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, et al.: Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: valsartan heart failure trial Val‐HeFT) echocardiographic data. J Am Coll Cardiol 2004; 43: 2022–2027. [DOI] [PubMed] [Google Scholar]
- 19. Yan RT, White M, Yan AT, Yusuf S, Rouleau JL, et al.: The RESOLVD Investigators: Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 2005; 96: 698–704. [DOI] [PubMed] [Google Scholar]
- 20. Perna ER, Macin SM, Cimbaro Canella JP, Alvarenga PM, Pantich RE, et al.: High levels of troponin T are associated with ventricular remodeling and adverse in‐hospital outcome in heart failure. Med Sci Monit 2004; 10: CR90–CR95. [PubMed] [Google Scholar]
- 21. Chong AY, Freestone B, Patel J, Lim HS, Hughes E, et al.: Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006; 97: 671–675. [DOI] [PubMed] [Google Scholar]
- 22. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, et al.: Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002; 105: 186–193. [DOI] [PubMed] [Google Scholar]
- 23. Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinetz T: Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005; 25: 1174–1179. [DOI] [PubMed] [Google Scholar]
- 24. Lowbeer C, Gistafsson SA, Seeberger A, Bouvier F, Hulting J: Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest 2004; 64: 667–676. [DOI] [PubMed] [Google Scholar]
- 25. Duman D, Tokay S, Toprak A, Duman D, Oktay A, et al.: Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 962–967. [DOI] [PubMed] [Google Scholar]
- 26. Feng J, Schaus BJ, Fallavollita JA, Lee T‐C, Canty JM: Preload induces troponin I degradation independently of myocardial ischemia. Circulation 2001; 103: 2035–2037. [DOI] [PubMed] [Google Scholar]
- 27. Anand IS, Fisher LD, Chiang Y‐T, Latini R, Masson S, et al.:, for the Val‐HeFT Investigators: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial. Circulation 2003; 107: 1278–1283. [DOI] [PubMed] [Google Scholar]
- 28. Davila DF, Nunez TJ, Oderman R, Mazzei de Davila CA: Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol 2005; 101: 343–346. [DOI] [PubMed] [Google Scholar]
- 29. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreria S, et al.: N‐Terminal‐pro‐brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168–2174. [DOI] [PubMed] [Google Scholar]
- 30. O'Brien RJ, Squire IB, Demme B, Davies JE, Ng LL: Pre‐discharge, but not admission levels of NT‐proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003; 5: 499–506. [DOI] [PubMed] [Google Scholar]
- 31. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, et al.: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N‐BNP) concentrations. Lancet 2000; 355: 1126–1130. [DOI] [PubMed] [Google Scholar]
- 32. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, et al.: Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976–982. [DOI] [PubMed] [Google Scholar]
- 33. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, et al.: Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594–600. [DOI] [PubMed] [Google Scholar]